RT Journal Article
T1 Pulmonary surfactant in asthma
A1 Blanco, Odalys
A1 Díaz Reyes, Mercyleidi
A1 Labrada, Alexis
A1 Autilio, Chiara
A1 Pérez Gil, Jesús
AB Pulmonary surfactant is vital in human respiration. It maintains alveoli and terminal conducting airways open and therefore promotes an efficient gas exchange and low resistance in the airways during breathing dynamics. Lack or dysfunction of the pulmonary surfactant system is associated with severe lung disorders. Surfactant ability to maintain low surface tension at the respiratory air-liquid interface, with subsequent good compliance and low resistance in the airways, is extremely important for asthmatic patients. A growing series of experimental evidence indicates that surfactant dysfunction, either associated with the causes or as a consequence of asthma, can contribute to constriction of airways and exacerbation of asthma. Modulation by surfactant of the innate and induced immune response is also an important element defining propensity, but also the resolution of asthmatic crisis. Limited trials indicate that administration of exogenous therapeutic surfactant may offer favorable pharmacological effects to asthmatic patients, possibly by two different mechanisms. On the one hand, it can restore endogenous surface activity and, on the other hand, properly modulate the immune system. The objective of the present review has been to summarize and update available concepts and evidence that support the relationship between pulmonary surfactant and asthma, with particular attention to the role of pulmonary surfactant in the mechanisms of asthma manifestations as well as in the design of innovative future therapies.
PB Elsevier
SN 0014-2999
YR 2025
FD 2025-08
LK https://hdl.handle.net/20.500.14352/124323
UL https://hdl.handle.net/20.500.14352/124323
LA eng
NO Blanco O, Díaz-Reyes M, Labrada A, Autilio C, Pérez-Gil J. Pulmonary surfactant in asthma. European Journal of Pharmacology 2025;1005:178064. https://doi.org/10.1016/j.ejphar.2025.178064.
NO Acknowledgments/Funding:The laboratories of the authors are partly funded by the National Program of Biotechnology, Pharmaceutical Industry, and Medical Technology of the Cuban Ministry of Science, Technology and Environment (PN385LH007-003) and the Spanish Ministry of Science and Innovation (PID2021-124932OB-100, PID2024-156556OB-I00).
NO Ministerio de Ciencia e Innovación (España)
NO Ministerio de Ciencia, Tecnología y Medioambiente (Cuba)
DS Docta Complutense
RD 30 dic 2025